STOCKHOLM, SE / ACCESS Newswire / September 1, 2026 / Vicore Pharma Holding AB (STO:VICO))(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the following upcoming healthcare conferences:
Wells Fargo Healthcare Conference
Location: Encore Boston Harbor, Boston, Mass.
Format: 1×1 meetings
Participation Date: Tuesday, September 8, 2026
Participant: Ahmed Mousa, Chief Executive Officer
Cantor Global Healthcare Conference
Location: Waldorf Astoria New York, New York, N.Y.
Format: Fireside chat and 1×1 meetings
Fireside Chat Date and Time: Friday, September 11, 2026, 9:45-10:15 AM ET
Webcast: Link
Participant: Ahmed Mousa, Chief Executive Officer
For more information, please contact:
Hans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.com
About Vicore Pharma
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com
Attachments
Vicore Pharma to Participate in Upcoming Healthcare Conferences
SOURCE: Vicore Pharma Holding
View the original press release on ACCESS Newswire
